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Pandemic (H1N1) 2009 affected Chile during the 
winter of 2009. The hospitalization rate was 0.56% overall 
and 3.47% for persons >60 years of age at risk for severe 
disease and death independent of concurrent conditions. 
Age >60 years was the major risk factor for death from 
pandemic (H1N1) 2009.
O
n April 23, 2009, the World Health Organization 
issued alerts about the emergence of pandemic (H1N1) 
2009. On May 17, during fall in the Southern Hemisphere, 
the ﬁ  rst case of this disease in Chile was identiﬁ  ed (1). 
Pandemic (H1N1) 2009 then replaced seasonal inﬂ  uenza, 
which had accounted for <1% of conﬁ  rmed  inﬂ  uenza 
cases in Chile (2). Immediately after the alerts, a national 
mandatory notiﬁ   cation system was started in Chile for 
inﬂ  uenza-like illness (ILI) cases and hospitalized persons 
with pandemic (H1N1) 2009 in public and private 
institutions. We analyzed data for patients with conﬁ  rmed 
pandemic (H1N1) 2009 hospitalized during epidemiologic 
weeks 20–32 (May 19–August 3), 2009.
The Study
ILI was deﬁ  ned as fever >38.5°C and cough plus >1 of 
the following: sore throat, headache, and myalgia. Severe 
inﬂ  uenza was deﬁ  ned as any case conﬁ  rmed by reverse 
transcription PCR in a hospitalized person. The National 
Ministry of Health provided oseltavimir to every patient >5 
years of age who had ILI. Approximately 80% of ILI cases 
corresponded to pandemic (H1N1) 2009 conﬁ  rmed by PCR 
in a pilot study.
All fatal cases included in the analysis occurred in 
persons whose deaths were directly attributable to inﬂ  uenza. 
Demographic data, clinical features, concurrent conditions, 
and number of consultations before hospitalization were 
recorded (3).
Denominators used for determining overall incidence 
rates and incidence rates by age group were based on the 
national census of 2002. Denominators used for determining 
rates for hospitalized case-patients and case-fatality rates 
(CFRs) were 80% of ILI cases reported to the Ministry of 
Health during the study. We conducted statistical analysis 
by using SPSS version 13.0 (SPSS Inc., Chicago, IL, USA) 
and Epi Info version 6 (Centers for Disease Control and 
Prevention, Atlanta, GA, USA).
During May 19–August 3, 2009, a total of 342,588 ILI 
cases were reported. Median age of case-patients was 20.4 
years (range <1–109 years). The overall attack rates were 
1.2% for pandemic (H1N1) 2009 and 0.4% for persons >60 
years of age. During the same period, 651,416 treatments 
with oseltamivir were reported. Treatment data indicated 
that the attack rate was 4%. 
A total of 1,585 persons conﬁ  rmed to have ILI were 
hospitalized. Median age was 33 years (range 11 days–94 
years), and 52% were women. Overall rate of hospitalization 
was 9.4/100,000 persons. Case-hospitalization rate was 
0.6% (3.5% for persons >60 years of age and 1.6% for 
children <5 years of age) (Figure 1). Pneumonia was the 
most common diagnosis at admission (77.3%). Underlying 
diseases were present in 560 (56.6%) of 989 case-patients, 
and 217 (22%) had >2 concurrent conditions.
A total of 130 hospitalized patients died (overall 
mortality rate  0.79/100,000 persons). Among these patients 
were 117 who died during the study period. Median age was 
47 years (range 4 months–89 years) for persons who died 
and 30 years (range <1–94 years) for persons who survived 
(p<0.0001). Forty-seven percent of patients who died were 
>49 years of age. CFR was 0.04%: the highest rate was for 
patients >60 years of age (0.44%; p<0.0000001), followed 
by persons 15–59 years of age (0.045%). CFR was 0.02% 
for children <5 years of age and 0.008% for children 5–14 
years of age (Figure 2). Fifty percent of all deaths were 
caused by severe respiratory failure.
Age was a risk factor for severe inﬂ  uenza and death. 
Patients >60 years of age and <5 years of age were at a 
higher risk for severe disease, and patients >60 years of 
age were at a higher risk for death. At least 1 concurrent 
condition was identiﬁ  ed as a risk factor for death from 
pandemic (H1N1) 2009. Eighty-four (87.5%) of 96 patients 
who died and 485 (54.3%) of 893 of patients who survived 
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had an underlying disease (odds ratio 5.89, 95% conﬁ  dence 
interval 3.08–11.52; p<0.00001). A concurrent condition 
was a risk only for persons 15–49 years of age (Table).
Mean time from onset of symptoms to hospitalization 
was 4.3 days (range 0–20 days) for persons who died and 
3.6 days (range 0–20 days) for persons who survived (p = 
0.03). Median time from onset of symptoms to beginning 
of treatment with oseltamivir was 3.0 days for persons who 
died and for those who survived.
Conclusions
The strength of this study was inclusion of nearly all 
patients with conﬁ   rmed severe pandemic (H1N1) 2009 
in Chile because of timely implementation of a national 
notiﬁ  cation system. The population studied included 97% 
of hospitalized patients with pandemic (H1N1) 2009.
Differences in attack rate (1.2% by reporting of 
ILI cases and 4% by amount of oseltamivir provided) 
might be explained by the fact that not all ILI cases were 
captured (≈20% were lost because of underreporting) by 
the notiﬁ  cation system and oseltamivir was prescribed to 
persons with illness not included in the ILI case deﬁ  nition. 
We demonstrated in a pilot study that ≈60%–70% of 
oseltamivir used complied with the case deﬁ  nition for ILI.
The  ﬁ  rst wave of pandemic (H1N1) 2009 in Chile 
showed the highest incidence rate in children 5–14 years 
of age; persons ≥60 years of age were least affected (2). 
However, our study identiﬁ  ed persons ≥60 years of age as 
at greatest risk for severe respiratory disease and death, 
despite the lower incidence rates. During the inﬂ  uenza 
pandemic, risk for illness in this age group was low but risk 
for severe disease and death was higher than in the other 
groups, independent of underlying diseases. This ﬁ  nding 
differs from results of a study in California, USA, in which 
persons >60 years of age did not have a high hospitalization 
rate (4). Our ﬁ  nding is consistent with those of a report on 
seasonal inﬂ  uenza in which risk for severe infection and 
hospitalization was highest for elderly persons (5).
Before April 2009, inﬂ   uenza was rarely reported 
as the cause of death in Chile. Therefore, only CFRs for 
severe respiratory infection are available for comparison. 
The CFRs for patients >65 years during winter 2009 was 
similar to that during previous winters. We conclude 
that elderly persons’ risk for a severe outcome during 
pandemic (H1N1) 2009 did not exceed this risk for a 
severe outcome during seasonal inﬂ  uenza. Previous reports 
have documented increased risk for severe outcomes 
in younger persons during pandemic (H1N1) 2009 and 
the absence of increased risk for disease severity among 
elderly persons (4,6,7). On the basis of these ﬁ  ndings, some 
institutions made policy decisions to exclude anyone >65 
years of age without concurrent conditions from satisfying 
recommendations for use of vaccine against pandemic 
(H1N1) 2009 because of absence of identiﬁ  ed increased 
risk for infection. Our study indicates an age >60 is the 
greatest risk factor for a severe outcome during pandemic 
(H1N1) 2009 and seasonal inﬂ  uenza.
Delay in medical care was another risk factor for 
death in this study. The number of consultations before 
admission did not differ between the groups, suggesting 
that patients who died sought medical care later than 
patients who survived. Thus, timely medical consultation 
affected patient outcome.
This study indicates that an age ≥60 years was the 
greatest risk for death associated with pandemic (H1N1) 
2009 inﬂ   uenza, similar to that for seasonal inﬂ  uenza. 
These results can be used for future planning strategies for 
inﬂ  uenza, strengthening the need for inﬂ  uenza vaccination, 
opportune medical evaluation, and timely therapy speciﬁ  c 
for this age group.
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Figure 1. Hospitalization rate for patients with pandemic (H1N1) 
2009, by age group among reported case-patients with inﬂ  uenza-
like illness, Chile, 2009.
Figure 2. Case-fata    lity rate for pandemic (H1N1) 2009 by age 
group among reported case-patients with inﬂ  uenza-like  illness, 
Chile, 2009.Additional members of the Advisory Committee of the 
Chilean Ministry of Health who contributed data to this study 
are Jorge Jimenez, Enrique Paris, and Carlos Pérez (Pontiﬁ  cia 
Universidad Católica de Chile, Santiago); Miguel O’Ryan 
(Universidad de Chile, Santiago); and Luis Miguel Noriega and 
Pablo Vial (Universidad del Desarrollo, Santiago).
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Table. Risk factors for severe disease or death among patients 
with pandemic (H1N1) 2009, Chile, 2009* 
Risk factor  OR (95% CI) 
Severe disease 
 Age  group,  y 
  <5  3.66  (3.27–4.11)† 
  5–14  0.22  (0.18–0.25) 
  15–59  0.89  (0.81–0.98) 
>60 7.94 (6.93–9.10)† 
Death 
  Age group, y  
  <15  0.17  (0.1–0.3) 
  15–59  1.44  (0.99–2.09) 
>60 15.06 (9.94–22.72)† 
 Concurrent  condition 
  All  patients  5.89  (3.08–11.52)† 
  Age  group,  y   
   <1  ND  (inexact)‡ 
   1–4  3.53  (0.24–101.6) 
   5–14  ND  (inexact)‡ 
   15–49  6.69  (2.4–20.0)† 
   50–64  2.39  (0.77–8.5) 
   >64  1.0  (0.18–7.0) 
*OR, odds ratio; CI, confidence interval; ND, not defined. 
†p<0.05. 
‡Not significant. 
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